The Power of Partnerships
EIN Presswire reports that POP Biotechnologies - a UB spinoff biopharmaceutical startup - announced positive top line interim results of a Phase 3 clinical trial of EuCorVac-19, a protein-based COVID-19 vaccine that uses POP BIO’s spontaneous-nanoliposome antigen particle (SNAP) technology. The vaccine is being developed by South Korean partner EuBiologics.
The phase 3 trial of EuCorVac-19 was conducted in the Philippines in approximately 2600 adults. Based on the results of this clinical study, EuBiologics plans to apply for product approval in the Philippines shortly. Later this year, results will become available from a second independent Phase 3 clinical study being carried out in the Democratic Republic of Congo.
POP BIO co-founder Jonathan Smyth shares, “Achieving the completion of this Phase III trial is an enormous milestone for our technologies. These results provide validation towards not only solving this unprecedented global crisis but also provides invaluable support towards our platform’s development, further enabling the creation of new vaccines with tremendous potential to alleviate suffering worldwide."